Over a 2-week period in March 2016, approximately 200 healthcare professionals completed the survey on the updated NICE type 2 diabetes guidelines published in November 2015. More than 85% were aware of the new guidelines. PCDS members were asked what part of the new NICE guidance was most different from their current clinical practice – 35% answered the new guidance on pioglitazone, closely followed by changes to the recommendations on individualisation (31%), glycaemic targets (30%) and sodium–glucose cotransporter 2 inhibitors (26%).
More than half of the PCDS members who responded and who are able to intensify treatment, or recommend intensification, tended to intensify to two agents when HbA1c was 58 mmol/mol (7.5%), which is the NICE recommendation. Respondents were also given the opportunity to expand their answer; 16% wrote that they took an individualised-approach to intensification taking into account age and other comorbidities. This is also in agreement with updated recommendations on individualisation of glycaemic control.
The NICE type 2 diabetes algorithm states that glucagon-like peptide (GLP)-1 receptor agonists should be considered if triple therapy (which may include insulin) fails in those on metformin, and BMI and other criteria are met (i.e. BMI is >35 kg/m2 and there are psychological or medical issues associated with obesity, or BMI is <35 kg/m2 and insulin therapy would have significant occupational implications, or weight loss would benefit other obesity-related comorbidities). The results of the survey show that 35% of respondents would use GLP-1 receptor agonists when all oral agents had failed (Figure 1a); however, a quarter would initiate, or refer for initiation of, a GLP-1 receptor agonist at first intensification and 41% at second intensification. Figure 1b shows respondents felt the updated treatment algorithm was the most useful part of the new guidance.
The mortality benefits of smoking cessation may be greater and accrue more rapidly than previously understood.
2 Apr 2024